Updated cost-effectiveness analysis of trastuzumab for early breast cancer: A UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence

PharmacoEconomics

Volumn 29, Issue 5, 2011, Pages 415-432

  Hall, Peter S ^a,c   Hulme, Claire ^a   McCabe, Christopher ^a   Oluboyede, Yemi ^a   Round, Jeff ^a   Cameron, David A ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Cost utility; Early breast cancer treatment; Trastuzumab therapeutic use

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HEALTH CARE COST; HEART FAILURE; HUMAN; LIFE EXPECTANCY; LIFESPAN; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; NEOPLASM RECURRENCE, LOCAL; TIME FACTORS;

EID: 79955063565     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11588340-000000000-00000     Document Type: Article

References (61)

1. Hall PS, Cameron DA. Current perspective: trastuzumab. Eur J Cancer 2009; 45 (1): 12-8
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353 (16): 1659-72 (Pubitemid 41464705)
3. Gianni L, Goldhirsch A, Gelber RD, et al. S25 update of the HERA trial and the role of 1 year trastuzumab as adjuvant therapy for breast cancer. Breast 2009; 18 Suppl. 1: S11
4. Slamon DEW, Robert N, Pienkowski T, et al., on behalf of BCIRG006 Investigators. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in her2neu positive early breast cancer patients: BCIRG 006 Study [abstract no. 62]. Cancer Res 2010; 69: 62
5. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353 (16): 1673-84 (Pubitemid 41464706)
6. Jones AL, Barlow M, Barrett-Lee PJ, et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updatedUnited KingdomNational CancerResearch Institute recommendations for monitoring. Br J Cancer 2009; 100 (5): 684-92
7. Suter TM, ProcterM, van Veldhuisen DJ, et al. Trastuzumabassociated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25 (25): 3859-65 (Pubitemid 47477261)
8. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in nodepositive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23 (31): 7811-9 (Pubitemid 46657378)
9. Ewer MS,OShaughnessy JA.Cardiac toxicity of trastuzumabrelated regimens in HER2-overexpressing breast cancer. Clin Breast Cancer 2007; 7 (8): 600-7
10. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Dec Making 1993; 13 (4): 322-38 (Pubitemid 24013155)
11. National Institute for Health Research. NIHR Health Technology Assessment Programme Details of HTA project in progress. PERSEPHONE: duration of trastuzumab study with chemotherapy in early breast cancer: six versus twelve months [online]. Available from URL: http://www. hta.ac.uk/1607 [Accessed 2010 Mar]
12. Skedgel C, Rayson D, Younis T. The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neupositive breast cancer: an analysis based on updated results from the HERA trial. Value Health 2009; 12 (5): 641-8
13. NorumJ, Olsen JA,Wist EA, et al. Trastuzumab in adjuvant breast cancer therapy: a model based cost-effectiveness analysis. Acta Oncol 2007; 46 (2): 153-64
14. Neyt M, Huybrechts M, Hulstaert F, et al. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Health Policy 2008; 87 (2): 146-59
15. Millar JA, Millward MJ. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model. Pharmacoeconomics 2007; 25 (5): 429-42 (Pubitemid 46744472)
16. Lidgren M, Jonsson B, Rehnberg C, et al. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol 2008; 19 (3): 487-95 (Pubitemid 351325669)
17. Liberato NL,Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2007; 25 (6): 625-33 (Pubitemid 350002916)
18. Kurian AW, Thompson RN, Gaw AF, et al. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol 2007; 25 (6): 634-41 (Pubitemid 350002917)
19. Garrison Jr LP, Lubeck D, Lalla D, et al. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment ofHER2-positive breast cancer. Cancer 2007; 110 (3): 489-98 (Pubitemid 47106136)
20. Elkin EB, Weinstein MC, Winer EP, et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2004; 22 (5): 854-63 (Pubitemid 41103597)
21. Dedes KJ, Szucs TD, Imesch P, et al. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Ann Oncol 2007; 18 (9): 1493-9 (Pubitemid 47365481)
22. McKeage K, Lyseng-Williamson KA. Trastuzumab: a pharmacoeconomic review of its use in early breast cancer. Pharmacoeconomics 2008; 26 (8): 699-719 (Pubitemid 351989060)
23. Shiroiwa T, Fukuda T, Shimozuma K, et al. The modelbased cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat 2008; 109 (3): 559-66 (Pubitemid 351692065)
24. National Institute for Health and Clinical Excellence. Early and locally advanced breast cancer: diagnosis and treatment [online]. Available from URL: http://guidance.nice. org.uk/CG80 [Accessed 2009 Dec 10]
25. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369 (9555): 29-36 (Pubitemid 46039831)
26. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000; 92 (24): 1991-8 (Pubitemid 32045895)
27. Cancer Research UK CancerStats [online]. Available from URL: http://info.cancerresearchuk.org/cancerstats [Accessed 2011 Feb 11]
28. Mellemkjaer L, Friis S, Olsen JH, et al. Risk of second cancer among women with breast cancer. Int J Cancer 2006; 118 (9): 2285-92
29. de Bock GH, Putter H, Bonnema J, et al. The impact of locoregional recurrences on metastatic progression in earlystage breast cancer: a multistate model. Breast Cancer Res Treat 2009; 117 (2): 401-8
30. Canney P, Linsday C, Wardley A, et al. Cardiac effects when using trial-derived monitoring protocols for adjuvant trastuzumab: results from a retrospective multicenter UK audit [abstract no. 582]. J Clin Oncol 2009; 27 (15 Suppl.): 582
31. Cowie MR, Wood DA, Coats AJS, et al. Incidence and aetiology of heart failure: a population-based study. Eur Heart J 1999; 20 (6): 421-8 (Pubitemid 29116538)
32. Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007; 25 (25): 3808-15 (Pubitemid 47477254)
33. Office of National Statistics. Interim life tables for England and Wales 2006-2008. Sheffield: UK Government [online]. Available from URL: http://www.statistics.gov.uk [Accessed 2009 Dec 10]
34. Cowie MR, Wood DA, Coats AJS, et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart 2000; 83 (5): 505-10 (Pubitemid 30316712)
35. Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010 Jan 1; 28 (1): 92-8
36. Niwińska A, Murawska M, Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 2010 May 21 5 942-8
37. Untch M, Gelber RD, Jackisch C, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008; 19 (6): 1090-6 (Pubitemid 351796334)
38. Lidgren M, Wilking N, Jonsson B, et al. Health related quality of life in different states of breast cancer. Qual Life Res 2007; 16 (6): 1073-81 (Pubitemid 47174889)
39. Calvert MJ, Freemantle N, Cleland JG. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study. Eur J Heart Fail 2005; 7 (2): 243-51 (Pubitemid 40215620)
40. Dinnes J, Cave C, Huang S, et al. The effectiveness and costeffectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review. Health Technol Assess 2001; 5 (13): 1-73
41. British National Formulary. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2008: 56
42. NHS. National health service executive. NHS reference costs, 2008. London: Department of Health, 2010
43. Lorgelly PK, Briggs AH, Wedel H, et al. An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. Eur J Heart Fail 2010; 12 (1): 66-74
44. Karnon J, Kerr GR, Jack W, et al. Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis. Br J Cancer 2007; 97 (4): 479-85 (Pubitemid 47258450)
45. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17 (5): 479-500 (Pubitemid 30398806)
46. Perez EA, Suman VJ, Davidson NE, et al. Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2- positive adjuvant breast cancer trial [abstract no. 80]. Cancer Res 2009; 69: 80
47. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial. J Clin Oncol 2008; 26 (8): 1231-8
48. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Handbooks in health economic evaluation. Oxford: Oxford University Press, 2006
49. Hall PS, McCabe C, Brown JM, et al. Health economics in drug development: efficient research to inform healthcare funding decisions. Eur J Cancer 2010; 46 (15): 2674-80
50. Coulson S, Kumar V, Coleman R. Treatment of HER2+ breast cancer in routine practice review of testing and use of adjuvant trastuzumab across a cancer network [abstract no. B16]. National Cancer Research Institute Conference; 2009 Oct 4-7; Birmingham
51. National Institute for Health and Clinical Excellence. Trastuzumab for the adjuvant treatment of early-stage HER2- positive breast cancer: NICE technology appraisal guidance
52. London: NICE, 2006
53. National Institute of Health and Clinical Excellence. Breast cancer (early) - trastuzumab: evidence review group report [online]. Available from URL: http://www.nice.org.uk/ni cemedia/live/11585/33454/33454.pdf [Accessed 2011 Feb 11]
54. Slamon DEW, Robert N, Pienkowski T, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AT/T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC/TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients [abstract no. 52]. Breast Cancer Treat Res 2006; 100 Suppl. 1: 52
55. Younis T, Skedgel C. Is trastuzumab a cost-effective treatment for breast cancer? Exp Rev Pharmacoeconomics Outcomes Res 2008; 8 (5): 433-42
56. Reed SD, Schulman KA. Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer. Value Health 2009; 12 (5): 637-40
57. Slamon DEW, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study [abstract no. 1]. Breast Cancer Res Treatment 2005; 94 Suppl. 1: S5
58. Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol 2009; 27 (34): 5685-92
59. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672-7
60. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia of childhood. N Engl J Med 1991; 324: 808-15
61. Goorin AM, Chauvenet AR, Perez-Atayde AR, et al. Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 1990; 116: 144-7 (Pubitemid 20038283)